Seonix Bio

About

Seonix Bio develops a clinical polygenic risk score test that quantifies glaucoma genetic risk from blood or saliva by analyzing thousands of SNPs to help clinicians prioritize high-risk patients.

Mission

Seonix Bio is developing a polygenic risk score (PRS) test that quantifies genetic risk of glaucoma from a blood or saliva sample by analysing thousands of SNPs. The PRS is based on research from Flinders University, QIMR Berghofer Medical Research Institute, SALHN within SA Health, and the University of Tasmania and was published in Nature Genetics. The company aims to enable clinicians to identify and prioritize patients at greatest risk so they can receive informed care sooner and reduce unnecessary investigations and treatments. Seonix Bio plans to deploy the PRS in the clinic and attain NATA accreditation to support clinical use. The company says the test could improve management and treatment of glaucoma patients while reducing health system costs. The Seed-Start grant from the South Australian government will fund these initial clinical rollout and accreditation steps.

Quick Facts